Business Context and Reporting Period
This Form 8-K is a current report filed by Bionexus Gene Lab Corp. (BGLC), a Wyoming corporation listed on The Nasdaq Stock Market LLC. The report date is December 27, 2024, with the signature date of December 31, 2024. The filing addresses a regulatory notice regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes and Regulatory Status
- Delisting Notice: The company received a written notice from the Nasdaq Hearings Panel regarding non-compliance with Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule), which requires a minimum bid price of $1.00 per share.
- Temporary Exception Granted: The Panel granted a temporary exception to regain compliance.
- Compliance Deadline: The company must regain compliance by May 1, 2025. Failure to do so will result in delisting from The Nasdaq Capital Market.
- Proposed Action: The company intends to effect a reverse stock split, if necessary, no later than April 7, 2025.
- Updated Rule Requirements: Effective January 30, 2025, the company must notify Nasdaq of specific details, including the date of shareholder approval, at least 10 calendar days prior to the anticipated market effective date of the reverse stock split.
Guidance, Outlook, and Risks
Management stated it is taking necessary steps to ensure compliance within the granted timeframe and will provide updates as appropriate. The primary risk identified is the potential delisting of common stock if the minimum bid price requirement is not met by the May 1, 2025 deadline. No financial guidance or outlook was provided in this filing.
Investor Verification Checklist
- Verify the current trading price of BGLC to assess the magnitude of the reverse stock split required.
- Monitor for a shareholder meeting notice regarding the proposed reverse stock split, required to be filed at least 10 days prior to the effective date.
- Confirm whether the company successfully regains compliance with the $1.00 bid price rule by May 1, 2025.
- Review the company's most recent 10-K or 10-Q for financial context, as this 8-K contains no financial data.